Autonomix Medical Q4'25 Revenue Estimate Hits Zero Amid Financial Woes
AMIX has more than doubled off its 52-week low of $0.2.
Summary
Autonomix Medical is facing a Q4'25 revenue estimate of $0, alongside an anticipated EPS of ($0.26). This estimate comes ahead of the company's earnings release on June 03. Given the company's existing going concern warning and short cash runway, a zero-revenue estimate highlights severe operational challenges and a complete lack of commercial activity. This stark financial outlook contrasts with recent positive news regarding patent grants and abstract selections for its medical technology. Traders will be watching the actual Q4'25 results on June 03 for confirmation.
At the time of this announcement, AMIX was trading at $0.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8M. The 52-week trading range was $0.20 to $2.64. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.